SCHEMBL6183524

SCHEMBL6183524

CC(CCNC(=O)c1ccc(-c2csc(NC3CCN(C(=O)OC(C)(C)C)CC3)n2)cc1)CC(=O)NC1(C#N)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 5/20 0.41
CTSL P07711 2/20 0.41
CTSB P07858 2/20 0.41
CTSS P25774 2/20 0.41
ITGB3 P05106 5/20 0.40
ITGA2B P08514 5/20 0.40
GPR119 Q8TDV5 2/20 0.39
HDAC4 P56524 2/20 0.38
IDH1 O75874 1/20 0.38
IDH2 P48735 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
USP30 Q70CQ3 1/20 0.37
HDAC1 Q13547 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182285 0.88 CTSB (0.47) CTSLCTSBCTSSMAPTMAPK1
SCHEMBL6182262 0.87 CTSL (0.48) CTSLCTSBCTSSGPR119USP30
SCHEMBL6185188 0.86 CTSS (0.42) CTSLCTSBCTSSITGB3ITGA2B
SCHEMBL7433953 0.82 ENPP2 (0.47) ENPP2CTSLCTSBCTSSITGB3
SCHEMBL6182261 0.82 ENPP2 (0.47) ENPP2CTSLCTSBCTSSITGB3
SCHEMBL6183519 0.81 ITGB3 (0.42) ENPP2ITGB3ITGA2BGPR119IDH1
SCHEMBL6183083 0.77 CTSS (0.49) CTSLCTSBCTSSMAPTMAPK1
SCHEMBL6182680 0.77 CTSB (0.64) CTSLCTSBCTSS
SCHEMBL6184409 0.77 CTSS (0.58) CTSLCTSBCTSS
SCHEMBL7616975 0.77 CTSS (0.51) CTSLCTSBCTSSALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 ENPP2 834/4885CTSL 14/4885CTSB 11/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 ENPP2 834/4885CTSL 14/4885CTSB 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.